Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - ulipristal acetate, quantity: 30 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; croscarmellose sodium; lactose monohydrate - ellaone is indicated for emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 702 mg (equivalent: abacavir, qty 600 mg); lamivudine, quantity: 300 mg; dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; magnesium stearate; purified water; mannitol; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in triumeq.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - magnesium sulfate heptahydrate, quantity: 500 mg/ml - injection, concentrated - excipient ingredients: water for injections - parenteral administration of magnesium is indicated in the treatment of acute hypomagnesaemia. magnesium salts are also indicated to prevent hypomagnesaemia in patients receiving total parenteral nutrition. magnesium sulphate is also indicated in the prevention and treatment of life-threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia). for emegency treatment of some arrhythmias such as torsade de pointes and those associated with hypokalemia.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - morphine sulfate pentahydrate, quantity: 10 mg/ml - injection, suspension - excipient ingredients: dioleoylphosphatidylcholine; dipalmitoylphosphatidylglycerol; cholesterol; triolein; tricaprylin; sodium chloride; dilute hydrochloric acid; water for injections - for the relief of post-operative pain following major orthopaedic, abdominal, or pelvic surgery via the lumbar epidural route at a maximum recommended dose of 10 mg. appropriate monitoring must be maintained for at least 48 hours - see precautions.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - quinine sulfate - oral tablet - 200mg